19 March 2024

cyclomedica
technegas

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

CYCLOPHARM ACHIEVES MILESTONE WITH FIRST USA PATIENTS IMAGED WITH TECHNEGAS

Cyclopharm today announces that its first USA Technegas clinical patients were imaged last week at two preeminent clinical sites located in St Louis, Missouri and Stanford, California.

These landmark events follow United States Food and Drug Administration approval of Technegas last October and the subsequent rollout of the company's plan for market penetration in medical facilities across the US - with work continuing to accelerate on converting strong clinical demand into contract signoff through varying approval phases at medical institutions across the USA.

These two locations represent the first clinical patients to be imaged in the US. They also signify immediate and ongoing clinical revenues for Technegas.

James McBrayer, Cyclopharm CEO said, "We are very pleased to see the clinical use of Technegas underway within days of installation and training at these sites and look forward to implementing Technegas to their affiliate locations in the coming months. Most significant is the fact that US patients are now benefitting from our Technegas technology, joining those in 64 other countries globally where our leading imaging solution is already established."

"We are grateful for the ongoing clinical guidance and partnership of the clinical leaders at these locations as well as for the support of the entire nuclear medicine and administration teams who have helped us navigate through the implementation process. We are very pleased that these sites are the first to use Technegas clinically in the United States," Mr McBrayer said.

- ENDS -

This ASX announcement was approved and authorized for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited
Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas® used in functional lung ventilation imaging.

Technegas®
The Technegas® technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700^{o} C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas®, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension, Long COVID and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

Technegas was recently approved for clinical use in the United States on 29 September 2023. The approved indication for use in the USA is as follows: *Technegas, when used with sodium pertechnetate Tc 99m in the Technegas Plus System, provides technetium Tc 99m-labeled carbon inhalation aerosol (Technegas Aerosol), a radioactive diagnostic agent for use in adults and pediatric patients aged 6 years and older for the visualization of pulmonary ventilation and evaluation of pulmonary embolism when paired with perfusion imaging.*